Occupational and Environmental Lung Disease¶
Chapter 300 | Part 7: Disorders of the Respiratory System
KEY CLINICAL POINTS¶
- Occupational and environmental lung diseases are often indistinguishable from non-environmental causes but require detailed exposure history for diagnosis.
- Asbestos exposure is linked to asbestosis, mesothelioma, and lung cancer with latency periods of 15–40 years.
- Silicosis and coal worker’s pneumoconiosis are progressive fibrotic diseases with additive risks from smoking.
- Diagnostic workup includes chest imaging, pulmonary function tests, and specific immune assays (e.g., BeLPT).
- Environmental exposures like biomass smoke and traffic pollution contribute significantly to global respiratory morbidity.
1. DEFINITION & OVERVIEW¶
Occupational and environmental lung diseases encompass conditions caused by workplace or environmental exposures to dust, chemicals, toxins, and pathogens. These diseases often mimic non-environmental pulmonary disorders but require detailed exposure history for accurate diagnosis. Environmental factors may interact with genetic and lifestyle factors (e.g., smoking) to exacerbate disease risk.
Table 299-4: Infectious Causes of Pulmonary Eosinophilia¶
| Infectious Agent | Clinical Features | Diagnostic Clues |
|---|---|---|
| Löffler Syndrome | Transient pulmonary infiltrates with eosinophilia | Helminthic larvae migration (Ascaris, hookworm) |
| Strongyloidiasis | Recurrent respiratory symptoms with peripheral eosinophilia | Chronic infection in immunocompromised hosts |
| Filariasis | Eosinophilic pneumonias with tropical travel history | Diethylcarbamazine treatment response |
| Paragonimiasis | Cough, hemoptysis, chest pain | Helminthic infection with lung migration |
| Dirofilariasis | Lung nodules with eosinophilia | Insect vector exposure |
1.1 Infectious Causes¶
Helminthic infections (e.g., Ascaris, Strongyloides), filarial infections, and fungal exposures (e.g., Paragonimiasis) are major infectious causes of pulmonary eosinophilia. Löffler syndrome is a transient condition caused by helminthic larvae migration through the lungs.
1.2 Drug and Toxin-Induced¶
Medications (e.g., NSAIDs, antibiotics) and environmental toxins (e.g., silica, asbestos) can cause interstitial lung disease, asthma, or hypersensitivity pneumonitis. Radiation therapy and occupational chemicals (e.g., beryllium) contribute to lung injury.
2. EPIDEMIOLOGY¶
Occupational lung diseases account for 10–20% of adult asthma and COPD cases. Asbestos-related diseases (e.g., asbestosis, mesothelioma) are more prevalent in developing countries. Biomass smoke exposure contributes to 4% of global deaths from pneumonia, COPD, and cardiovascular disease. Environmental pollutants (e.g., PM2.5, ozone) affect 90% of the world’s population.
2.1 Risk Factors¶
Occupational exposures (e.g., silica, asbestos, coal dust), environmental pollutants (e.g., traffic emissions, biomass smoke), and genetic susceptibility (e.g., HLA-DP alleles) increase disease risk. Smoking synergizes with occupational exposures to accelerate lung damage.
2.2 Demographics¶
Asbestosis and silicosis are more common in male workers, while women are disproportionately affected by biomass smoke-related COPD. Occupational asthma is prevalent in agricultural and manufacturing sectors.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Pathogenesis involves oxidative stress, immune dysregulation, and fibrosis. Asbestos fibers induce fibrosis via reactive oxygen species and macrophage dysfunction. Silica exposure causes alveolar macrophage dysfunction, increasing infection risk. Beryllium induces granulomatous inflammation via T-cell hypersensitivity.
Table 300-1: Occupational Exposures and Respiratory Conditions¶
| Occupational Exposure | Respiratory Response | Comments |
|---|---|---|
| Asbestos (mining, construction) | Asbestosis, mesothelioma, lung cancer | High risk in developing countries |
| Silica (mining, sandblasting) | Silicosis, PMF, tuberculosis | Improved protection in the U.S. |
| Coal dust (mining) | Coal worker’s pneumoconiosis, COPD | Persistent risk in U.S. coal regions |
| Beryllium (aerospace, electronics) | CBD, granulomatous disease | High-tech industry risk |
| Cotton dust (textile) | Byssinosis, COPD | Risk in developing countries |
3.1 Asbestos Pathogenesis¶
Asbestos fibers trigger chronic inflammation, oxidative stress, and fibrosis. Mesothelioma develops from prolonged exposure ( ≥ 10 years) with latency of 15–40 years. Smoking synergizes with asbestos to increase lung cancer risk.
3.2 Silica-Induced Injury¶
Silica particles cause alveolar macrophage dysfunction, leading to fibrosis and increased susceptibility to infections (e.g., tuberculosis). PMF (progressive massive fibrosis) develops from prolonged exposure (>15 years).
4. CLINICAL FEATURES¶
Symptoms vary by etiology: cough, dyspnea, chest pain, and eosinophilia. Asbestosis presents with restrictive lung disease; silicosis with progressive fibrosis. Hypersensitivity pneumonitis (e.g., farmer’s lung) features acute or chronic interstitial inflammation.
4.1 Asbestosis¶
Chest radiograph shows pleural plaques and linear opacities. HRCT reveals subpleural reticulation. Pulmonary function tests show restrictive pattern with reduced DLCO.
4.2 Silicosis¶
Acute silicosis presents with miliary infiltrates; chronic silicosis with nodular fibrosis. HRCT shows “crazy paving” pattern. PMF leads to severe restrictive lung disease.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include hypersensitivity pneumonitis, sarcoidosis, and interstitial lung disease. Key differentiators: occupational history, imaging patterns (e.g., pleural plaques for asbestosis), and specific immune assays (e.g., BeLPT for CBD).
5.1 Hypersensitivity Pneumonitis vs. Sarcoidosis¶
Hypersensitivity pneumonitis shows granulomas with fungal antigens; sarcoidosis has noncaseating granulomas. Both may present with interstitial lung disease but differ in etiology and immune markers.
5.2 Asbestosis vs. Silicosis¶
Asbestosis has pleural plaques and linear opacities; silicosis shows nodular fibrosis. Both cause restrictive lung disease but differ in etiology and progression.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes chest imaging (HRCT), pulmonary function tests, and specific tests (e.g., BeLPT for CBD). Biomarkers like serum IgE and eosinophil counts aid in diagnosing allergic or eosinophilic conditions.
Table 300-2: Toxic Chemical Agents and Lung Effects¶
| Toxin | Acute Effects | Chronic Effects |
|---|---|---|
| Isocyanates (TDI, MDI) | Bronchospasm, pulmonary edema | Asthma, hypersensitivity pneumonitis |
| Silica | Alveolar macrophage dysfunction | Silicosis, tuberculosis |
| Asbestos | Pleural plaques, fibrosis | Mesothelioma, lung cancer |
| Biomass smoke | Chronic bronchitis, COPD | Interstitial lung disease |
| Radon | Lung cancer | Pulmonary fibrosis |
6.1 Imaging¶
Chest radiograph identifies pleural plaques (asbestosis), nodules (silicosis), and interstitial patterns. HRCT provides detailed assessment of fibrosis and granulomas.
6.2 Laboratory Tests¶
BeLPT confirms beryllium sensitivity. Serum IgE and eosinophil counts help diagnose hypersensitivity pneumonitis. Bronchoscopy with biopsy may be required for definitive diagnosis.
7. MANAGEMENT & TREATMENT¶
Management focuses on removing the offending exposure, supportive care, and specific therapies (e.g., corticosteroids for hypersensitivity pneumonitis). For silicosis, whole-lung lavage may provide symptomatic relief. Beryllium exposure requires strict avoidance and monitoring.
7.1 Asbestos-Related Disease¶
Avoid further exposure. Corticosteroids for acute inflammation. Lung transplantation may be considered for severe fibrosis. Mesothelioma treatment includes surgery, chemotherapy, and radiation.
7.2 Silicosis¶
Discontinue silica exposure. Whole-lung lavage for acute cases. Supportive care for chronic cases. Vaccination against tuberculosis is critical due to increased infection risk.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by disease: asbestosis and silicosis have progressive fibrosis with high mortality. Mesothelioma is fatal within 1–2 years. Complications include respiratory failure, infections, and malignancy. Early intervention improves outcomes.
8.1 Asbestosis¶
Progressive fibrosis leads to respiratory failure. Mortality is 50% within 10 years of diagnosis. Smoking synergizes to accelerate disease progression.
8.2 Silicosis¶
Acute silicosis has a 50% mortality rate within 1–2 years. Chronic silicosis progresses to PMF with severe restrictive lung disease. Tuberculosis risk is 5–10 times higher.
9. SPECIAL CONSIDERATIONS¶
Occupational lung diseases require workplace intervention and legal compensation. Pregnant workers may face risks from certain exposures (e.g., asbestos). Environmental factors like biomass smoke disproportionately affect women and children in developing countries.
9.1 Legal and Financial Implications¶
Occupational lung diseases may qualify for workers’ compensation. Legal action may be required for asbestos-related mesothelioma. Environmental exposure claims (e.g., burn pits) are complex and require detailed documentation.
9.2 Global Health Impact¶
Household air pollution from biomass fuels causes 4% of global deaths. Environmental policies (e.g., PM2.5 standards) are critical for reducing respiratory morbidity.
10. KEY POINTS & CLINICAL PEARLS¶
- Occupational and environmental lung diseases require detailed exposure history for diagnosis.
- Asbestos and silica exposure are major causes of interstitial lung disease and cancer.
- Beryllium sensitivity is confirmed by BeLPT, and CBD requires strict avoidance.
- Environmental pollutants (e.g., PM2.5, biomass smoke) contribute significantly to global respiratory disease.
- Early intervention and workplace modification are critical for improving outcomes.